• Adipose Tissue: A Metabolic Regulator. Potential Implications for the Metabolic Outcome of Subjects Born Small for Gestational Age (SGA).
  (Maiorana A, et.al. Rev Diabet Stud. 2007 Fall;4(3):134-46. Epub 2007 Nov 10.)
  View Abstract

• Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
  (Lage MJ, et.al. Urology. 2007 Dec;70(6):1104-8.)
  View Abstract
• Disorders of glucose metabolism and risk of oral cancer.
  (Suba Z, et.al. Fogorv Sz. 2007 Oct;100(5):250-7, 243-9. Review. English, Hungarian.)
  View Abstract
• Metabolic syndrome and cancer risk.
  (Russo A, et.al. Eur J Cancer. 2007 Dec 3; [Epub ahead of print])
  View Abstract
• Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines.
  (Girroir EE, et.al. Toxicology. 2008 Jan 14;243(1-2):236-43. Epub 2007 Nov 4.)
  View Abstract
• Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease?
  (Oeffinger KC.Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):462-7; discussion 468.)
  View Abstract

• Depression, the Metabolic Syndrome and Cardiovascular Risk.
  (Vaccarino V, et.al. Psychosom Med. 2007 Dec 24; [Epub ahead of print])
  View Abstract
• Metabolic syndrome, insulin resistance, and brachial artery vasodilator function in framingham offspring participants without clinical evidence of cardiovascular disease.
  (Hamburg NM, et.al. Am J Cardiol. 2008 Jan 1;101(1):82-8.)
  View Abstract
• Alterations in cell adhesion molecules and other biomarkers of cardiovascular disease in patients with metabolic syndrome.
  (Gómez Rosso L, et.al. Atherosclerosis. 2007 Dec 18; [Epub ahead of print])
  View Abstract
• Vitamin D and cardiovascular disease risk.
  (Michos ED, et.al. Curr Opin Clin Nutr Metab Care. 2008 Jan;11(1):7-12.)
  View Abstract

• Metabolic Syndrome and Vascular Alterations in Normotensive Subjects at Risk of Diabetes Mellitus.
  (Ghiadoni L, et.al. Hypertension. 2007 Dec 24; [Epub ahead of print])
  View Abstract
• Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes.
  (Palumbo PJ.Am J Med Sci. 2007 Dec;334(6):466-80.)
  View Abstract
• Lessons that can be learned from patients with diabetogenic mutations in mitochondrial DNA: implications for common type 2 diabetes.
  (Maassen JA, et.al. Curr Opin Clin Nutr Metab Care. 2007 Nov;10(6):693-7.)
  View Abstract
• Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes.
  (Osawa H, et.al. Clin Endocrinol (Oxf). 2007 Dec 6; [Epub ahead of print])
  View Abstract
• Relationship between Metabolic Syndrome Categorized by Newly Recommended by International Diabetes Federation Criteria with Plasma Homocysteine Concentration.
  (Rhee EJ, et.al. Endocr J. 2007 Dec 4; [Epub ahead of print])
  View Abstract
• Heart failure in diabetes and related conditions.
  (Kamalesh M.J Card Fail. 2007 Dec;13(10):861-73.)
  View Abstract
• Modulation of glucocorticoid action and the treatment of type-2 diabetes.
  (Tomlinson JW, et.al. Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):607-19.)
  View Abstract
• Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
  (Arca M.Drugs. 2007;67 Suppl 1:43-54.)
  View Abstract

• Clinical Benefit of a Short Term Dietary Oatmeal Intervention in Patients with Type 2 Diabetes and Severe Insulin Resistance: A Pilot Study.
  (Lammert A, et.al. Exp Clin Endocrinol Diabetes. 2007 Dec 20; [Epub ahead of print])
  View Abstract
• Postnatal programming of glucocorticoid metabolism in rats modulates high-fat diet-induced regulation of visceral adipose tissue glucocorticoid exposure and sensitivity, and adiponectin and pro-inflammatory adipokines gene expression in adulthood.
  (Boullu-Ciocca S, et.al. Diabetes. 2007 Dec 5; [Epub ahead of print])
  View Abstract
• Nateglinide prevents fatty liver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat diet.
  (Mine T, et.al. Metabolism. 2008 Jan;57(1):140-8.)
  View Abstract

• Plasma Uric Acid and the Risk of Type 2 Diabetes in a Chinese Community.
  (Chien KL, et.al. Clin Chem. 2007 Dec 18; [Epub ahead of print])
  View Abstract
• The Metabolic Syndrome and Dyslipidemia Among Asian Indians: A Population With High Rates of Diabetes and Premature Coronary Artery Disease.
  (Enas EA, et.al. J Cardiometab Syndr. 2007 Fall;2(4):267-275.)
  View Abstract
• Diabetes mellitus in Asian Indian children and adolescents.
  (Nandkeoliar MK, et.al. J Pediatr Endocrinol Metab. 2007 Oct;20(10):1109-14.)
  View Abstract
• Apolipoprotein A5 IVS3+476A Allelic Variant Associates With Increased Trigliceride Levels and Confers Risk for Development of Metabolic Syndrome in Hungarians.
  (Kisfali P, et.al. Circ J. 2008 Jan;72(1):40-3.)
  View Abstract

• Exercise Training Amount and Intensity Effects on Metabolic Syndrome (from Studies of a Targeted Risk Reduction Intervention through Defined Exercise).
  (Johnson JL, et.al. Am J Cardiol. 2007 Dec 15;100(12):1759-66. Epub 2007 Oct 29.)
  View Abstract
• The Italian Diabetes and Exercise Study (IDES): Design and methods for a prospective Italian multicentre trial of intensive lifestyle intervention in people with type 2 diabetes and the metabolic syndrome.
  (Balducci S, et.al. Nutr Metab Cardiovasc Dis. 2007 Nov 29; [Epub ahead of print])
  View Abstract
• Associations between abdominal adiposity, exercise, morbidity, and mortality.
  (Kuk JL.Appl Physiol Nutr Metab. 2007 Dec;32(6):1210-1.)
  View Abstract

• The Effect of Plasminogen Activator Inhibitor-1 675 4G/5G Polymorphism on PAI-1 Gene Expression and Adipocyte Differentiation.
  (Ozel Demiralp D, et.al. Clin Appl Thromb Hemost. 2007 Dec 26; [Epub ahead of print])
  View Abstract
• Association of Angiotensin-converting enzyme gene insertion/deletion polymorphism with metabolic syndrome in iranians with type 2 diabetes mellitus.
  (Nikzamir A, et.al. Arch Iran Med. 2008 Jan;11(1):3-9.)
  View Abstract
• USF1 gene variants contribute to metabolic traits in men in a longitudinal 32-year follow-up study.
  (Auro K, et.al. Diabetologia. 2007 Dec 21; [Epub ahead of print])
  View Abstract
• Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample.
  (Pollex RL, et.al. BMC Med Genet. 2007 Dec 20;8(1):80 [Epub ahead of print])
  View Abstract
• Gene expression profile in obesity and type 2 diabetes mellitus.
  (Das UN, et.al. Lipids Health Dis. 2007 Dec 14;6(1):35 [Epub ahead of print])
  View Abstract
• Association between polymorphisms in the Clock gene, obesity and the metabolic syndrome in man.
  (Scott EM, et.al. Int J Obes (Lond). 2007 Dec 11; [Epub ahead of print])
  View Abstract

• Relationship Between the Metabolic Syndrome and the Development of Hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study-2 (CRISPS2).
  (Cheung BM, et.al. Am J Hypertens. 2008 Jan;21(1):17-22.)
  View Abstract
• Undiagnosed obesity in hypertension: Clinical and therapeutic implications.
  (Romero R, et.al. Blood Press. 2007;16(6):347-53.)
  View Abstract

• Association between proinsulin, insulin, proinsulin/insulin ratio, and insulin resistance status with the metabolic syndrome.
  (Pivatto I, et.al. Arq Bras Endocrinol Metabol. 2007 Oct;51(7):1128-1133.)
  View Abstract
• Metabolic consequences of hyperglycemia and insulin resistance.
  (Jellinger PS.Clin Cornerstone. 2007;8 Suppl 7:S30-42.)
  View Abstract
• Melatonin-insulin interactions in patients with metabolic syndrome.
  (Robeva R, et.al. J Pineal Res. 2008 Jan;44(1):52-6.)
  View Abstract
• FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases.
  (Ni YG, et.al. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20517-22. Epub 2007 Dec 12.)
  View Abstract
• Insulin resistance and metabolic syndrome in patients with NAFLD but without diabetes: effect of a 6 month regime intervention.
  (Cankurtaran M, et.al. Acta Gastroenterol Belg. 2007 Jul-Sep;70(3):253-9.)
  View Abstract
• ICER-1gamma overexpression drives palmitate-mediated connexin36 down-regulation in insulin-secreting cells.
  (Allagnat F, et.al. J Biol Chem. 2007 Dec 11; [Epub ahead of print])
  View Abstract
• Role of adipocytokines in obesity-associated insulin resistance.
  (Zou C, et.al. J Nutr Biochem. 2007 Nov 26; [Epub ahead of print])
  View Abstract
• Inflammation and insulin resistance.
  (de Luca C, et.al. FEBS Lett. 2008 Jan 9;582(1):97-105. Epub 2007 Nov 29.)
  View Abstract
• Effect of Ramadan fasting on some indices of insulin resistance and components of the metabolic syndrome in healthy male adults.
  (Shariatpanahi ZV, et.al. Br J Nutr. 2007 Dec 6;:1-5 [Epub ahead of print])
  View Abstract
• Hyperlipidemia is associated with altered levels of insulin-like growth factor-I.
  (Malík J, et.al. Physiol Res. 2007 Nov 30; [Epub ahead of print])
  View Abstract

• Confusion in Revascularization: Are Women Different and Why?
  (Dullum MK, et.al. Cardiol Rev. 2008 January/February;16(1):30-35.)
  View Abstract
• Endothelium-dependent vasodilatation in formerly preeclamptic women correlates inversely with body mass index and varies independently of plasma volume.
  (Lommerse T, et.al. Reprod Sci. 2007 Dec;14(8):765-70.)
  View Abstract
• Uric acid: A surrogate of insulin resistance in older women.
  (Chen LK, et.al. Maturitas. 2007 Dec 12; [Epub ahead of print])
  View Abstract
• Metabolic syndrome: do clinical criteria identify similar individuals among overweight premenopausal women?
  (Alhassan S, et.al. Metabolism. 2008 Jan;57(1):49-56.)
  View Abstract
• Effects of spironolactone on glucose transport and interleukin-6 secretion in adipose cells of women.
  (Corbould A.Horm Metab Res. 2007 Dec;39(12):915-8.)
  View Abstract
• Behavior of insulin sensitivity and its relation to leptin and tumor necrosis factor-alpha in obese women undergoing liposuction: 6-month follow-up.
  (Robles-Cervantes JA, et.al. Obes Surg. 2007 Sep;17(9):1242-7.)
  View Abstract
• The increasing prevalence of metabolic syndrome among Finnish men and women over a decade.
  (Hu G, et.al. J Clin Endocrinol Metab. 2007 Dec 11; [Epub ahead of print])
  View Abstract
• Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists.
  (Collins P, et.al. Climacteric. 2007 Dec;10(6):508-26.)
  View Abstract
• Gestational diabetes, inflammation, and late vascular disease.
  (Volpe L, et.al. J Endocrinol Invest. 2007 Nov;30(10):873-9.)
  View Abstract
• Body iron stores in relation to the metabolic syndrome, glycemic control and complications in female patients with type 2 diabetes.
  (Mojiminiyi OA, et.al. Nutr Metab Cardiovasc Dis. 2007 Dec 4; [Epub ahead of print])
  View Abstract

• Plasma Plasminogen Activator Inhibitor-1 Levels and Nonalcoholic Fatty Liver in Individuals With Features of Metabolic Syndrome.
  (de Larranaga G, et.al. Clin Appl Thromb Hemost. 2007 Dec 26; [Epub ahead of print])
  View Abstract
• Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach.
  (Bellentani S, et.al. Hepatology. 2007 Dec 20; [Epub ahead of print])
  View Abstract
• Nonalcoholic Fatty Liver Disease Induced by Leuprorelin Acetate.
  (Gabbi C, et.al. J Clin Gastroenterol. 2008 Jan;42(1):107-110.)
  View Abstract
• Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis.
  (Manco M, et.al. Int J Obes (Lond). 2007 Dec 18; [Epub ahead of print])
  View Abstract
• Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies.
  (Fan JG, et.al. Hepatobiliary Pancreat Dis Int. 2007 Dec;6(6):572-8.)
  View Abstract
• Activation and Dysregulation of the Unfolded Protein Response in Nonalcoholic Fatty Liver Disease.
  (Puri P, et.al. Gastroenterology. 2007 Oct 26; [Epub ahead of print])
  View Abstract
• Nonalcoholic Fatty Liver Disease: Pathogenesis and Potential for Nuclear Receptors as Therapeutic Targets.
  (George J, et.al. Mol Pharm. 2007 Dec 12; [Epub ahead of print])
  View Abstract
• SHOULD NONALCOHOLIC FATTY LIVER DISEASE BE INCLUDED IN THE DEFINITION OF METABOLIC SYNDROME? A CROSS-SECTIONAL COMPARISON WITH ATP III CRITERIA IN NONOBESE NONDIABETIC SUBJECTS.
  (Musso G, et.al. Diabetes Care. 2007 Dec 4; [Epub ahead of print])
  View Abstract
• Liver fattening during feast and famine: An evolutionary paradox.
  (van Ginneken VJ.Med Hypotheses. 2007 Dec 1; [Epub ahead of print])
  View Abstract

• Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome.
  (Vemuri VK, et.al. Physiol Behav. 2007 Nov 21; [Epub ahead of print])
  View Abstract
• Overweight adolescents: a group at risk for metabolic syndrome (tehran adolescent obesity study).
  (Moayeri H, et.al. Arch Iran Med. 2008 Jan;11(1):10-5.)
  View Abstract
• Inflammation, obesity, and fatty acid metabolism: influence of n-3 polyunsaturated fatty acids on factors contributing to metabolic syndrome.
  (Robinson LE, et.al. Appl Physiol Nutr Metab. 2007 Dec;32(6):1008-1024.)
  View Abstract
• Effective cut-off values of waist circumference to detect the clustering of cardiovascular risk factors of metabolic syndrome in Japanese men and women.
  (Lee JS, et.al. Diab Vasc Dis Res. 2007 Dec;4(4):340-5.)
  View Abstract

• Prevalence of the Metabolic Syndrome Among U.S. Adolescents Using the Definition from the International Diabetes Federation.
  (Ford ES, et.al. Diabetes Care. 2007 Dec 10; [Epub ahead of print])
  View Abstract
• Impaired glucose tolerance and risk factors for progression to type 2 diabetes in youth.
  (Weiss R.Pediatr Diabetes. 2007 Dec;8 Suppl 9:70-5.)
  View Abstract
• Arterial structure and function in young adults with the metabolic syndrome: the Cardiovascular Risk in Young Finns Study.
  (Mattsson N, et.al. Eur Heart J. 2007 Dec 15; [Epub ahead of print])
  View Abstract

• Reduced high-molecular weight adiponectin and elevated hsCRP are synergistic risk factors for metabolic syndrome in a large scale middle-aged to elderly population: the J-SHIPP study.
  (Tabara Y, et.al. J Clin Endocrinol Metab. 2007 Dec 26; [Epub ahead of print])
  View Abstract
• Metabolic syndrome: are we at risk?
  (Paudel B.Nepal Med Coll J. 2007 Sep;9(3):204-11.)
  View Abstract
• Impact of metabolic syndrome risk factors in first-degree relatives of type 2 diabetic patients.
  (Siewert S, et.al. Rev Diabet Stud. 2007 Fall;4(3):177-84. Epub 2007 Nov 10.)
  View Abstract
• Metabolic syndrome and ischemic stroke risk: northern Manhattan study.
  (Boden-Albala B, et.al. Stroke. 2008 Jan;39(1):30-5. Epub 2007 Dec 6.)
  View Abstract
• Metabolic syndrome: identifying the risk factors.
  (Lottenberg SA, et.al. J Pediatr (Rio J). 2007 Nov;83(5 Suppl):S204-8.)
  View Abstract
• Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults.
  (Tozawa M, et.al. Hypertens Res. 2007 Oct;30(10):937-43.)
  View Abstract
• Prognostic Relevance of Metabolic Syndrome in Hypertensive Patients at Low-to-Medium Risk.
  (Pierdomenico SD, et.al. Am J Hypertens. 2007 Dec;20(12):1291-1296.)
  View Abstract
• Body-mass index, waist-size, waist-hip ratio and cardiovascular risk factors in urban subejcts.
  (Gupta R, et.al. J Assoc Physicians India. 2007 Sep;55:621-7.)
  View Abstract

Sleep Disorders

• The reciprocal interaction between sleep and type 2 diabetes mellitus: facts and perspectives.
  (Martins RC, et.al. Braz J Med Biol Res. 2007 Nov 27; [Epub ahead of print])
  View Abstract